Pediatric Neurology News

The FDA has granted final approval to Zydus for Sabril, an anticonvulsant used to treat children aged 1 month to 2 years with infantile spasms.

An integrated ambulatory care model that had infusion capacity for pediatric refractory headache appeared feasible and beneficial for these patients, according to a quality improvement study.

Few randomized clinical trials support using repository corticotropin injection for most FDA-approved indications, including rheumatoid arthritis, ankylosing spondylitis, lupus, optic neuritis and nephrotic syndrome, according to researchers.

Individuals with pediatric-onset MS may exhibit disturbances in their gut microbiome, according to study results published in Neurology.

Healio Neurology’s five most-viewed stories in December highlight a study on increased sun exposure lowering children’s MS risk, FDA approval of a treatment for myasthenia gravis and research on a self-administered examination that may quickly identify mild cognitive impairment conversion to dementia.

Parents commonly reported sleep concerns that persisted with age for children with early-life epilepsies, according to study results published in Pediatric Neurology.

Age at pediatric stroke has a significant impact on post-stroke recovery and affects long-term cognitive outcome regardless of lesion size and lesion location, according to results of a cross-sectional study published in Neurology.

Increased sunlight exposure may offer significant protection against development of pediatric MS, according to study results published in Neurology.

Extracardiac anomalies, including structural brain anomalies, were frequently detected on fetal MRI among fetuses with various forms of congenital heart disease, researchers reported.

Specialty epilepsy care availability increased in the U.S. following implementation of the National Association of Epilepsy Centers’ accreditation program, according to study results published in Neurology.